All In Biotech

Drug Trial Radar · NCT04414163

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

23

Actual

Start

Oct 27, 2020

Primary completion

Jul 23, 2024

Study completion Feb 28, 2027

Sponsor

Lead sponsor
ImmuneOncia Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Extranodal NK/T-cell Lymphoma

Interventions

  • IMC-001Drug

    Single dose level for enrollment subject (IMC-001 20mg/kg every 2 weeks)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Objective Response Rate(ORR)Time frame: through study completion, an average of 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Chonnam National University Hwasun Hospital

    Gwangju, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Ulsan University Hospital

    Ulsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.